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a  b  s  t  r  a  c  t
Despite  signiﬁcant  advances  in  the physician’s  ability  to initiate  myocardial  reperfusion  and  salvage
heart  tissue,  ischemic  heart  disease  remains  one  of the  leading  causes  of death  in  the  United  States.
Consequently,  alternative  therapeutic  strategies  have  been  intensively  investigated,  especially  methods
of enhancing  the heart’s  resistance  to ischemic  cell  death  – so  called  “cardioprotective”  interventions.
However,  although  a great  deal  has been  learned  regarding  the  methods  and  mechanisms  of  cardiopro-
tective  interventions,  an  efﬁcacious  therapy  has  yet  to be  successfully  implemented  in the  clinical  arena.eywords:
yocardial infarction
ardioprotection
eperfusion injury
schemia–reperfusion
ytoskeletal signaling
This  review  discusses  the  current  understanding  of  cardioprotection  in the  context  of  ischemic  heart  dis-
ease  pathophysiology,  highlighting  those  elements  of  ischemic  heart  disease  pathophysiology  that  have
received  less  attention  as  potential  targets  of  cardioprotective  intervention.
©  2014  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).schemic preconditioning
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mpact of ischemic heart disease
Heart disease is the leading cause of death in the United States,
nd ischemia/reperfusion-induced cell death (IR), such as seen
the remaining viable myocytes to work harder to maintain sufﬁ-
cient cardiac output. To accomplish this, these remaining myocytes
hypertrophy to increase their strength of contraction. While this
remodeling is initially adaptive, in severe cases this remodelinguring myocardial infarction (MI), is a major cause of morbid-
ty and mortality, as about 1.5 million Americans suffer from an
I annually [1–3]. Because terminally differentiated myocytes do
ot regenerate, the loss of myocardial tissue due to MI  forces
∗ Corresponding author at: Department of Pathology, 1901 Perdido Street, New
rleans, LA 70112, United States. Tel.: +1 504 568 6033; fax: +1 504 568 6037.
E-mail address: rvand3@lsuhsc.edu (R.S. Vander Heide).
ttp://dx.doi.org/10.1016/j.phrs.2014.08.004
043-6618/© 2014 Published by Elsevier Ltd. This is an open access article under the CC Bcan decompensate and become pathological, ultimately leading
to heart failure [3]. Thus, the best strategy to improve both sur-
vival and quality of life in patients suffering from MI  is to minimize
myocardial death that occurs due to IR. Clinically, this is achieved
through arterial reperfusion of the ischemic myocardium which,
in most cases, is accomplished through active dissolution and/or
physical obliteration of an occlusive intracoronary lesion. Since
the therapeutic importance of prompt myocardial reperfusion has
been emphasized and implemented into today’s standard of care,
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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he morbidity and mortality of MI  has decreased. Aiding that
ecrease has been reﬁnement in the techniques physicians employ
o re-establish coronary blood ﬂow, including the development
f percutaneous coronary angioplasty and coronary stenting, as
ell as the administration of pharmacological adjuvants, such as
ntiplatelet therapeutics, that help maintain vessel patency [4].
owever, as the prevalence of major risk factors for ischemic heart
isease, most notably diabetes, hyperlipidemia and hypertension,
ontinues to be substantial, the burden of disease for MI  will remain
igniﬁcant.
Because further advances in methods to provide prompt
yocardial reperfusion in patients suffering from MI  are unlikely
o yield signiﬁcant beneﬁts in morbidity and mortality, there is a
reat need for the development of novel ischemic heart disease
herapies [4]. Consequently, many researchers have investigated
trategies that can make the heart more resistant to ischemic death
 so called “cardioprotective” interventions. While many cardio-
rotective strategies have been identiﬁed in the laboratory setting,
ttempts to translate these protective laboratory interventions into
 successful clinical therapy have been largely unsuccessful. While
easons for this lack of success may  be due to the inherent difﬁculty
f translating results generated in tightly controlled animal mod-
ls into a heterogeneous patient population [5], the lack of success
ay  also be attributed, in part, to an incomplete understanding of
ow cardioprotective signaling may  be initiated at the level of the
ardiac myocyte in response to myocardial stress. Thus, there is
reat interest in elucidating the mechanisms by which IR induces
ethal cellular injury and how cardioprotection may  be elicited in
he myocardium to allow for the identiﬁcation of novel targets for
schemic heart disease therapy. Accordingly, the goal of this review
s to highlight these potential avenues of cardioprotection in the
ontext of MI  pathophysiology.
athology of myocardial infarction
schemic cell death
Myocardial ischemia results in numerous deleterious conse-
uences at the level of the cardiac myocyte that, if left uncorrected,
ulminate in necrotic cell death. A major consequence of myocar-
ial ischemia is the depletion of adenosine triphosphate (ATP)
nd other high energy phosphates due to cessation of aerobic
etabolism and oxidative phosphorylation. Because the contin-
ally contracting myocardium is highly dependent on aerobic
etabolism, ATP depletion occurs rapidly in the ischemic heart
nd contractility is halted within 60 s. ATP depletion has numer-
us detrimental effects on myocyte biochemistry and metabolism,
ncluding relaxation of myoﬁlaments, glycogen depletion, disrup-
ion of ionic equilibrium and cell swelling. Nevertheless, these
ffects can be reversed and normal myocyte contractile function
estored if the duration of ischemia is sufﬁciently brief (generally
onsidered to be less than 20 min  of severe ischemia). However, if
he ischemia is prolonged, irreversible injury will develop, which
s characterized by damage and/or disruption of the myocyte sar-
olemmal membrane. Plasma membrane damage leads to loss of
smotic balance and the leakage of cellular metabolites into the
xtracellular space. Damage to the mitochondrial membranes com-
romises the cell’s ability to generate ATP upon reperfusion, as
ell as results in release of mitochondrial proteins that can directly
timulate the apoptotic cell death pathway. Disruption of lysoso-
al  membranes is especially dire, as this can lead to the release
f degradative enzymes capable of digesting essentially all cellular
onstituents, invariably leading to cellular necrosis [6].
In addition to necrosis, apoptosis also contributes signiﬁcantly
o myocyte death during IR, although the exact contributions ofological Research 89 (2014) 36–45 37
each during the sustained ischemic episode and during myocar-
dial reperfusion remain unclear. While apoptotic myocyte death is
most pronounced in the reperfused myocardium [7,8], apoptosis
has also been shown to contribute to cell death in ischemic-only
hearts [9]. Some studies suggest there may  be overlap between
the early signaling events that lead to either necrosis or apoptosis,
as interventions known to inhibit apoptosis, such as Bcl-2 overex-
pression, have also been demonstrated to reduce cellular necrosis
[10,11]. Other investigators propose that, during myocardial IR, the
distinction between apoptosis and necrosis becomes blurred, as
injured cells attempting to undergo apoptosis may  be unable to
maintain plasma membrane integrity, resulting in necrosis instead
[12]. In addition, a more recently deﬁned form of cell death known
as necroptosis or “programmed necrosis,” a form of cell death with
characteristics of both necrosis and apoptosis, has been suggested
to contribute to myocyte death during IR [13–15].
Although the determining factors by which IR will lead to either
necrotic or apoptotic cell death are not completely understood, it
is known that both ischemia and reperfusion result in substantial
ionic changes capable of predisposing the cardiac myocyte to both
forms of cell death. Ischemia causes a cessation of aerobic respira-
tion and a shift to of anaerobic respiration, resulting in depletion of
glycogen stores and a resulting accumulation of hydrogen ions and
tissue acidosis [5,16–18]. To counterbalance this acidosis, Na+/H+
exchange occurs at the sarcolemmal membrane, with the efﬂux
of H+ balanced by the inﬂux of Na+ and resulting in an accumula-
tion of intracellular ions relative to the extracellular environment.
As a result of the accumulation of Na+ ions, reverse action of the
Na+/Ca2+ exchanger (NCX) is stimulated, which leads to an accumu-
lation of intracellular Ca2+ as the accumulated Na+ is extruded from
the cell in exchange for extracellular Ca2+. Compounding these ionic
disturbances is the depletion of high energy phosphates that occurs
rapidly in the ischemic myocardium, preventing the normal activ-
ity of the Na+/K+ ATPase, ATP-dependent reuptake of calcium at the
sarcoplasmic reticulum and active Ca2+ excretion [16,19], resulting
in further exacerbation of intracellular Na+ and Ca2+ accumulation.
As the calcium concentration within the cytosol continues to rise,
mitochondria begin to passively uptake calcium into the mitochon-
drial matrix via the mitochondrial calcium uniporter [18]. If the
ischemia is severe and these ionic imbalances are sustained, this
cytosolic and mitochondrial calcium overload will ultimately lead
to irreversible cellular injury as described below.
Loss of myocyte calcium homeostasis results in a number
of cellular changes that predispose the myocyte to irreversible
injury. Mitochondrial calcium overload is the primary stimulus
for mitochondrial permeability transition (MPT), a stress response
mediated by the opening of a high conductance pore located on
the inner mitochondrial membrane (discussed further in Section
“Reperfusion injury: calcium overload”). While enhanced intra-
cellular calcium concentration is capable of directly stimulating
apoptosis [20], elevated calcium levels can also stimulate the
activation of numerous intracellular degradative enzymes with
the potential to damage several different cellular structures and
precipitate cell death, including phospholipases, proteases and
endonucleases. Activation of phospholipases can lead to the dam-
age of cellular membranes which, as described above, can lead
to necrotic cell death as a consequence of disruption of cellular
osmotic balance and the release of lysosomal enzymes in the cyto-
plasm [6]. The ionic imbalances engendered by ischemia and the
consequent causes of ischemic myocyte death are summarized in
Fig. 1.Reperfusion injury
Studies conducted by Jennings and Reimer in the late 1960s
and 1970s were pivotal for demonstrating the time-dependent
38 A.J. Perricone, R.S. Vander Heide / Pharmacological Research 89 (2014) 36–45
Fig. 1. Causes and consequences of ionic imbalances during ischemia. Ischemia
results in a cessation of aerobic metabolism and a reliance on anaerobic metabolism,
resulting in cellular and tissue acidosis. Accumulation of intracellular H+ stimulates
NHE, resulting in accumulation of intracellular Na+. Accumulation of intracellu-
lar  Na+, in turn, stimulates reverse activity of the NCX, resulting in intracellular
Ca2+ accumulation. If ischemia is sustained, cellular Ca2+ overload may  develop,
resulting in activation of degradative enzymes (e.g., proteases, phosphatases and
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Fig. 2. Primary mediators of lethal reperfusion injury. Oxidative stress results in
sensitization of mitochondria to MPT  as well as direct damage to membrane phos-
pholipids. The abrupt correction of acidosis relieves an inhibitory inﬂuence on MPT
and degradative enzymes and serves as an important impetus for calcium overload.
Calcium overload can culminate in cell death through varying mechanisms, includ-
ing activation of calpain proteases, MPT  and hypercontracture of fragile myocytes.
oxidative stress and high energy phosphate depletion sensitizendonucleases), and stimulation of MPT, culminating in myocyte death. NHE, Na+/H+
xchanger; NCX, Na+/Ca2+ exchanger; MPT, mitochondrial permeability transition.
rogression of myocardial necrosis as the index ischemia was
xtended and the critical importance of prompt reperfusion for sal-
aging myocardium [21,22]. Interestingly, in an even earlier study
onducted by Jennings et al. in 1960, it was observed that reper-
used myocardium displayed a more advanced injury pattern than
yocardium subjected to the same ischemic duration that had not
een reperfused [23]. Speciﬁcally, it was observed that reperfused
yocardium displayed myocyte swelling, plasma membrane dis-
uption and dense mitochondrial bodies – histological features that
o not manifest in the absence of reperfusion unless ischemia is
xtended for a much longer duration. This observation led others
o later hypothesize that reperfusion could result in lethal myocar-
ial injury above and beyond that due to the ischemic insult alone
 a concept known as lethal reperfusion injury.
The mechanisms of lethal reperfusion injury have been well
tudied in an effort to discern if the conditions of myocardial reper-
usion could be modiﬁed to maximize the salvage of ischemic
yocytes. Chief among the primary mediators of reperfusion injury
re the rapid correction of intracellular acidosis, myocyte calcium
verload and oxidative stress [5,24]. The primary mediators of
ethal reperfusion injury are depicted in Fig. 2.
eperfusion injury: correction of intracellular pH
While the acidotic conditions of the ischemic myocyte pre-
ipitate ionic imbalance and cell swelling, intracellular myocyte
cidosis also inhibits several subcellular processes which can
otentially culminate in irreversible injury. Acidosis reduces the
everse activity of the NCX, thereby attenuating calcium overload
19]. Furthermore, H+ ion accumulation directly inhibits MPT  [25],
stensibly by interfering with the binding of calcium to the MPT
rigger site. The acidotic cytosolic environment of the ischemic
yocyte also inhibits the activation of proteases called calpains calcium-dependent enzymes which are capable of digesting
nd weakening the myocyte’s cytoskeletal support [26,27]. How-
ver, upon reperfusion there is rapid washout of accumulated H+Activation of calpains can result in additional damage to the myocyte cytoskeleton,
predisposing myocytes to rupture of the sarcolemma following imposed mechanical
stress, such as cell swelling or hypercontracture.
ions, alleviating the acidotic inhibition and predisposing reperfused
myocytes to cellular injury.
Reperfusion injury: calcium overload
As discussed above, the accumulation of calcium during
ischemia occurs as a result of the reverse mode of the NCX.
In addition, ATP depletion and subsequent cessation of active
calcium extrusion and ATP-dependent reuptake into the sarcoplas-
mic  reticulum further contribute to myocyte calcium overload.
Unfortunately, upon reperfusion, this myocyte calcium overload
is not corrected, but rather is further exacerbated. At reperfusion,
extracellular washout of accumulated H+ ions establishes a large
gradient greatly favoring the inﬂux of sodium via the Na+/H+
exchanger and leading to the rapid correction of cellular pH. This
sudden and robust inﬂux of sodium strongly stimulates the reverse
action of the NCX, especially now that the acidotic inhibition of
the NCX has been relieved, resulting in even greater elevations
of intracellular calcium concentration [16]. Enhanced cytosolic
calcium levels favor the electrophoretic uptake of calcium into
mitochondria via the mitochondrial calcium uniporter [20]. The
end result is cytosolic and mitochondrial calcium overload, cul-
minating in irreversible myocyte injury through many different
potential mechanisms including induction of MPT, activation of cal-
pains and myocyte hypercontracture. Each of these mechanisms is
discussed further below. Fig. 3 summarizes the establishment and
consequences of calcium overload during reperfusion.
MPT  is a prominent cause of irreversible cell injury elicited by
IR and is characterized by the opening of a high conductance, non-
speciﬁc pore located within the inner mitochondrial membrane.
While calcium overload is the primary determinant of MPT, there
are other cellular conditions that can inﬂuence the calcium con-
centration threshold necessary to induce MPT. For example, bothmitochondria to permeability transition, lowering the calcium con-
centration threshold necessary to induce MPT  [28]. Importantly,
in addition to the robust inﬂux of calcium that may  occur upon
A.J. Perricone, R.S. Vander Heide / Pharmac
Fig. 3. Causes and consequences of ionic imbalances during reperfusion. Reper-
fusion results in an abrupt alleviation of tissue acidosis and a washout of
extracellular H+, establishing a highly favorable gradient for Na+ inﬂux via the NHE.
The resulting Na+ accumulation potently stimulates reverse NCX activity, resulting
in Ca2+ overload. Ca2+ overload in the setting of reperfusion results in activation
of  the calcium dependent proteases calpains, the activity of which is attenuated in
the acidotic conditions of ischemia. The cellular milieu during reperfusion (e.g., Ca2+
overload, oxidative stress and alleviation of acidosis) is particularly well-suited for
the induction of MPT. Finally, resumption of contractile activity in the presence of
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la overload results in hypercontracture, imposing a signiﬁcant physical strain on
 weakened myocyte cellular architecture. NHE, Na+/H+ exchanger; NCX, Na+/Ca2+
xchanger; MPT, mitochondrial permeability transition.
eperfusion, oxidative stress and high energy phosphate deple-
ion are both present at reperfusion, highlighting the fact that
he cellular milieu is particularly well-suited for mitochondria to
ndergo MPT  following reperfusion. Indeed, many studies have
emonstrated that MPT  occurs upon reperfusion, primarily in ex
ivo models of myocardial IR [29,30].
MPT  results in the uncoupling of the mitochondrial membrane
otential, as the enhanced inner membrane permeability dissi-
ates the proton gradient necessary for oxidative phosphorylation.
urthermore, because the mitochondrial matrix exerts a positive
olloidal osmotic pressure due to its higher protein concentration
han either the cytosol or intermembranous space, MPT  results in
arked mitochondrial swelling [6,28]. While the inner mitochon-
rial membrane can withstand this swelling without rupturing by
irtue of “unfolding” of the cristae of the inner membrane, mito-
hondrial swelling is capable of rupturing the outer mitochondrial
embrane, which leads to the release of cytochrome c and the
timulation of the intrinsic apoptotic pathway [31]. As mitochon-
ria undergo MPT, swelling, and outer membrane rupture, more
alcium is released from these “open” mitochondria back into
he cytosol which, in turn, predisposes mitochondria that have
o far remained “closed” to undergo MPT. If a critical number of
itochondria undergo MPT, the most likely outcome is bioener-
etic failure of the myocyte and necrotic cell death [28].
The presence of myocyte calcium overload upon reperfusion can
lso lead to the activation of members of the calcium-dependent
amily of cysteine proteases known as calpains. -Calpain and m-
alpain are the most abundant calpain isoforms, both of which are
xpressed in the heart [27]. Calpains can become activated as a
esult of the calcium accumulation that occurs during ischemia
s well as the more robust increase in calcium inﬂux that occurs
uring reperfusion [5]. Calpain activation results in the hydrol-
sis of a number of proteins that predispose the myocyte to
ethal reperfusion injury. Chief among these calpain substrates areological Research 89 (2014) 36–45 39
cytoskeletal proteins, the enzymatic cleavage of which damages
myocyte contractile machinery and weakens myocyte structural
support [32,33]. This latter consequence is particularly trouble-
some as it can potentially lead to the rupture of the sarcolemmal
membrane upon the resumption of contractile activity [26].
Studies have supported a role for cytoskeletal lesions as impor-
tant mediators of irreversible IR injury. Seminal studies conducted
by Vander Heide and Ganote demonstrated using a Langendorff
perfused rat heart model that anoxic perfusion results in enhanced
myocardial fragility and decreased resistance to applied mechan-
ical force. Electron microscopy of hearts subjected to anoxic
perfusion prior to mechanical stress displayed rupture of the sar-
colemmal membrane and the formation of large subsarcolemmal
blebs caused by detachment of the sarcolemmal membrane from
the Z-disk [34]. A similar study conducted by Steenbergen et al.
at nearly the same time correlated the appearance of subsarcolem-
mal  blebs and plasma membrane rupture induced by ischemia with
the breakdown of vinculin, a focal adhesion cytoskeletal scaffolding
protein, at the plasma membrane [35]. Thus, while the exact series
of events that underlie the transition from reversible to irreversible
injury during ischemia are not completely understood, studies
support a role of cytoskeletal lesions as critical determinants of
irreversible ischemic injury that manifests upon reperfusion.
Further compounding the problem of enhanced myocyte
fragility during IR is the development of hypercontracture, a state of
nonphysiologic myocyte sarcomere shortening due to ATP gener-
ation in a setting of intracellular calcium overload [24,36,37]. The
concept that myocyte contracture can lead to irreversible injury
and sarcolemmal membrane rupture in the reperfused ischemic
myocyte by imposing a great physical stress on an already frag-
ile sarcolemmal membrane was originally postulated by Ganote
and Kaltenbach in 1979 [38]. Subsequent studies supported this
hypothesis by demonstrating that the calcium paradox, a phe-
nomenon by which the readmission of calcium to calcium depleted
hearts results in contraction band necrosis, was reproduced simply
with caffeine-stimulated sarcoplasmic reticulum calcium release
and resulting myocyte contracture and occurred independently of
extracellular calcium repletion [39,40]. Furthermore, a study by
Garcia-Dorado et al. demonstrated that attenuation of myocyte
contractility at reperfusion signiﬁcantly reduced infarct size in an
in vivo porcine model of MI  [41].
Reperfusion injury: oxidative stress
While reactive oxygen species (ROS) are generated during nor-
mal  cellular metabolism, the reperfusion of ischemic myocytes
results in a sudden burst of ROS which overwhelms the cell’s
capacity to scavenge these radicals, especially since the activity
of scavenging enzymes is attenuated as a result of the ischemic
insult [42]. Consequently, the reperfused myocyte enters a state
of oxidative stress, resulting in a number of deleterious conse-
quences that can culminate in lethal reperfusion injury. First, in
addition to mitochondrial calcium overload, this sudden onset of
oxidative stress sensitizes mitochondria to permeability transition
[28]. Mitochondria that undergo permeability transition can, in
turn, release additional free oxygen radicals that can sensitize other
mitochondria to MPT; this phenomenon is termed “ROS-induced
ROS release” [43]. Furthermore, ROS can directly damage calcium
handling proteins, thereby contributing to calcium overload at
reperfusion [5,42]. Importantly, ROS are capable of peroxidizing
membrane lipids, contributing to the disruption of cellular mem-
branes that occurs during IR [42]. Finally, ROS are also capable
of inﬂicting further cellular damage by cross-linking proteins and
creating DNA breaks [6].
There are multiple sources of increased ROS in the reperfused
myocyte. Xanthine oxidase is one prominent contributor of oxy-
gen radicals at reperfusion [16,44]. Normally, this enzyme exists
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n its dehydrogenase form, which oxidizes hypoxanthine while
sing NAD+ as its electron acceptor. However, during ischemia, a
alcium-dependent protease converts xanthine dehydrogenase to
anthine oxidase, an enzyme which oxidizes hypoxanthine while
educing O2 to O2− [44,45]. During ischemia, the degradation of
denine nucleotides results in a buildup of hypoxanthine, the
rimary substrate for xanthine oxidase. Thus, the sudden rein-
roduction of oxygen at reperfusion results in an abundance of
anthine oxidase substrates, hypoxanthine and O2, largely con-
ributing to the observed oxidative burst at reperfusion [44].
amage to mitochondria during the ischemic episode may  elicit
ncreased ROS generation directly from the electron transport
hain as a result of incomplete reduction of oxygen [6,42]. Finally,
schemic myocardial injury results in the inﬂux of leukocytes into
he ischemic risk region upon reperfusion. These inﬂammatory
ells are subsequently activated and become another important
ource of ROS generation through the action of the enzyme NADPH
xidase [42].
echanisms of cardioprotection
Because the best strategy for improving the morbidity and mor-
ality of MI  is to minimize the ischemic death of myocardial tissue,
here has been great research interest in learning how the heart
an be protected from ischemic death. Various laboratory inter-
entions have been shown to be capable of reducing infarct size
ncluding hypothermia [46], heat stress [47] and ischemic precon-
itioning (IP) [48], as well as a myriad of pharmacologic agents,
ncluding calcium channel blockers [49], adenosine [50], alpha 1
drenergic agonists [51] and delta 1 opioid agonists [52]. However,
mong these interventions, IP has demonstrated the most consis-
ent ability to confer robust cardioprotection in several different
ammalian models, including rats, rabbits, dogs, pigs, sheep and
onkeys [53]. Importantly, the ability of IP to confer protection has
lso been supported in humans undergoing coronary artery bypass
urgery, as patients subjected to an IP protocol displayed reduced
TP depletion following a controlled ischemic stress produced dur-
ng the normal course of the surgery [54]. Although the clinical
alue of IP is limited by the fact that patients suffering from MI  do
ot present until after the onset of ischemia, the discovery of IP pro-
ided deﬁnitive proof that the heart can be protected from ischemic
eath, spawning intensive research focused on elucidating these
rotective mechanisms.
schemic preconditioning and cardioprotective signaling
The phenomenon of IP was originally described by Murry et al.
n 1986 [48]. Following the original description of IP, it was  dis-
overed that the protection afforded by IP is not monophasic, but
ather IP produces two temporally distinct windows of cardio-
rotection. The ﬁrst window of protection begins within minutes
ollowing the cycles of preconditioning. This early window of
rotection is lost if the time between the cycles of precondition-
ng and the sustained myocardial ischemia is extended beyond
–2 h. The second window of protection develops 6–12 h follow-
ng IP and lasts for 3–4 days. The mechanisms mediating early
nd late preconditioning are distinct: the protection within the
arly window is associated with post-translational modiﬁcation
f pre-existing proteins, while the late window of protection is
hought to be produced through changes in gene expression and
he synthesis of new proteins, notably inducible nitric oxide syn-
hase (iNOS) and cyclo-oxygenase 2 (COX-2) [55]. This review
ocuses on cardioprotective signaling cascades elicited by acute
yocardial stress and therefore will discuss IP in context of the
arly window of cardioprotection as originally described by Murry
t al.ological Research 89 (2014) 36–45
The mechanism of IP’s protective effect has been extensively
investigated, and the research leading up to the present under-
standing of IP’s protective mechanism is brieﬂy summarized below.
IP’s cardioprotection is currently thought to be triggered through
the release of ischemic metabolites during the index ischemia and
the subsequent binding to their respective transmembrane recep-
tors. Adenosine was  the ﬁrst such metabolite to be recognized
for having cardioprotective potential [50]. Later, other metabolite
triggers were described, including bradykinin [56] and opioids [57].
This ability of multiple triggers to mimic  the protective effect of IP
led to the conclusion that the respective signaling pathways con-
verge downstream at a common point. Protein kinase C (PKC) was
one of the ﬁrst proposed points of convergence, as PKC inhibitors
are not only capable of abolishing the protective effect of IP [58],
but also the protection afforded by pharmacological mimickers of
IP [59]. PKC has been postulated to elicit cardioprotection, in part,
by activating mitochondrial ATP-sensitive K+ channels (mitoKATP)
[60]. The cardioprotection associated with mitoKATP is not com-
pletely understood, but activation of mitoKATP has been suggested
to enhance the resistance of mitochondria to MPT. mitoKATP chan-
nel opening results in an inﬂux of K+ into the mitochondrial matrix,
thereby depolarizing the mitochondrial membrane potential. This
depolarization, in turn, mitigates the driving force of calcium
into the mitochondrial matrix during the sustained ischemic
episode, thereby attenuating mitochondrial calcium overload and
decreasing the likelihood of MPT  occurring upon reperfusion [61].
In addition to PKC, several other downstream effector proteins
have been implicated as mediators of cardioprotective signaling
elicited by IP. Because phosphatidylinositol-3-kinase (PI3K), a lipid
kinase implicated in cell survival signaling [62], had been reported
to activate PKC, Tong et al. investigated the role of PI3K in IP-
elicited cardioprotection. Using a Langendorff perfused adult rat
heart model, they found that IP induced the activation of the cardio-
protective proteins Akt and PKC- and that the activation of these
proteins was blocked by pharmacological inhibition of PI3K. PI3K
inhibition also abolished the protective effect of IP on ventricu-
lar functional recovery, further implicating PI3K as an important
mediator of IP-elicited cardioprotection [63].
Concurrent to the research investigating the mechanism by
which IP induces cardioprotection, other animal research emerged
that demonstrated that various interventions initiated at the
onset of reperfusion, notably the administration of insulin [64],
insulin-like growth factor-1 (IGF-1) [65], bradykinin [66] and
the hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor atorvastatin [67], also protected the myocardium from
lethal IR injury. Importantly, research into the mechanism of these
protective interventions revealed that in each case either PI3K/Akt
and/or ERK 1/2 signaling was  involved in mediating the conferred
cardioprotection. Because PI3K/Akt signaling had been previously
implicated in mediating the protective effect of IP when stimulated
during the preconditioning phase [63], Hausenloy et al. postulated
that these survival kinases could stimulate cardioprotection not
only when activated during the cycles of preconditioning, but also
when activated at the onset of reperfusion [68]. Indeed, a subse-
quent study by Hausenloy et al. found that activated Akt and ERK
1/2 expression displayed a biphasic pattern with expression sig-
niﬁcantly enhanced both immediately following preconditioning
and again at the onset of reperfusion [69]. Because activation of
both PI3K/Akt and ERK 1/2 at reperfusion was demonstrated to
reduce infarct size, these signaling kinases were termed “reper-
fusion injury salvage kinases” or RISKs. Importantly, this study
demonstrated for the ﬁrst time that IP may  elicit cardioprotection
by mitigating reperfusion injury. This conclusion led to the formu-
lation of the hypothesis that the robust protective effect of IP can
be triggered at the onset of reperfusion, a viable target for clinical
intervention.
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The mechanisms responsible for the cardioprotection associ-
ted with RISK activation have been well studied. Although strong
vidence consistently supports a cardioprotective role of PI3K/Akt
ignaling, the evidence surrounding ERK signaling is somewhat
onﬂicting. While most data indicate that ERK is important in car-
ioprotective signaling [69,70], other studies have not supported a
ausal role of ERK signaling in mediating IP-elicited cardioprotec-
ion [71,72]. The cardioprotective phenotype associated with ERK
ignaling is not completely understood, but thought to be due to its
bility to inhibit pro-apoptotic proteins such as BAD [68,73]. The
rotective effect of PI3K is largely attributed to its ability to stim-
late the downstream activation of the serine/threonine protein
inase Akt, also known as protein kinase B, a well-established car-
ioprotective signaling molecule [74,75]. Akt is thought to provide
rotection from IR injury through multiple different mechanisms,
ncluding inhibition of apoptosis [74], stimulation of nitric oxide
ynthesis [76] and prevention of MPT  through phosphorylation and
nhibition of glycogen synthase kinase 3 (GSK-3) [77,78].
In addition to the well characterized cardioprotective role of
ISK signaling, recent evidence has implicated reversible cysteine
edox-based mechanisms of post-translational modiﬁcations, such
s S-nitrosylation (SNO) and S-glutathionylation, in mediating car-
ioprotection. Strong evidence supports SNO in particular as an
mportant contributor to preconditioning-elicited cardioprotec-
ion. SNO, a process in which NO forms a covalent bond with
he thiol groups of cysteine residues, is thought to mediate pro-
ection from IR injury by preventing the irreversible oxidation
f protein thiols during periods of oxidative stress, such as dur-
ng the respiratory burst of early myocardial reperfusion [79].
urthermore, SNO of the L-type calcium channel [80] and SR/ER
alcium-ATPase [81] results in decreased cytosolic inﬂux of calcium
nd increased uptake of calcium into the sarcoplasmic reticulum
espectively, thereby attenuating cellular calcium overload dur-
ng IR [79]. Importantly, studies have shown that SNO is enhanced
n the preconditioned heart and that induction of SNO during IR
esults in reduced ischemic cell death [81,82].
argeting ischemia–reperfusion injury-clinical trials
The discovery by Hausenloy and Yellon that IP-elicited car-
ioprotection could be aborted by inhibition of RISK signaling
t reperfusion, along with numerous studies demonstrating that
herapies initiated at reperfusion onset are protective, strongly
enewed interest in investigating the pathology of lethal reper-
usion injury and how it could be prevented or attenuated.
onsequently, the therapeutic potential of methods and therapies
apable of mimicking IP and eliciting cardioprotective signaling at
eperfusion has been intensively evaluated by numerous animal
tudies and clinical trials. The ﬁndings of these studies have been
horoughly discussed by several excellent reviews to which the
eader is directed [4,5,73,83], and these studies will not be reviewed
ere. Instead, this review will focus on studies examining the car-
ioprotective potential of interventions capable of interfering with
ediators of reperfusion injury, including correction of acidosis,
alcium overload, oxidative stress and MPT. The results of these
tudies are summarized in Table 1.
Perhaps the best demonstration that modiﬁcation of the con-
itions of reperfusion can result in signiﬁcant cardioprotection is
 phenomenon known as ischemic postconditioning (PostC). In an
ffort to enhance the clinical value of IP, Zhao et al. investigated
hether subjecting the heart to cycles of preconditioning follow-
ng the sustained coronary occlusion could result in infarct size
eduction. Using an open chest canine model of MI,  they found
hat PostC, performed by subjecting the heart to three cycles of
0 s of reperfusion and 30 s of coronary re-occlusion immediately
ollowing a 60 min  coronary occlusion, resulted in signiﬁcantological Research 89 (2014) 36–45 41
reduction in infarct size, comparable to the protection afforded by
IP [84].
Shortly after Zhao and colleague’s description of PostC, clinical
trials were underway to determine the clinical efﬁcacy of PostC. The
results of these clinical trials have been variable, with some trials
showing improved patient outcomes [85,86] and others showing
no difference in patient outcomes between the PostC and placebo
groups [87,88]. Reasons for the variability of results between tri-
als may  be due to the small number of patients enrolled in each
of the trials and/or differences in inclusion criteria and comorbidi-
ties of the enrolled patient populations. Regardless, PostC may offer
a therapeutic beneﬁt in speciﬁc patient populations undergoing
angioplasty for the treatment of acute MI.  However, it should be
noted that the therapeutic utility of PostC is limited in the clinical
arena, as patients must be undergoing angioplasty in a catheteriza-
tion lab to receive the therapy. Patients who require thrombolytic
therapy for restoration of coronary blood ﬂow cannot beneﬁt from
PostC. Thus, a therapeutic strategy that could be employed in all
patients regardless of how blood ﬂow is restored to the ischemic
myocardium would be preferable to PostC [4].
As discussed above, the rapid correction of ischemic acido-
sis at reperfusion can result in irreversible injury to myocytes by
stimulating calcium overload and cellular swelling while concomi-
tantly alleviating the acidotic inhibition of MPT  and calpains. Thus,
investigators hypothesized that by curbing the effects of ischemic
acidosis through inhibition of Na+–H+ exchange myocytes could
be protected from reperfusion injury. An early study by Karmazyn
demonstrated that amiloride, an inhibitor of the Na+–H+ exchanger
(NHE), administered at reperfusion improved post-ischemic ven-
tricular recovery [89]. Later, Wang et al. demonstrated that NHE-1
knockout (KO) mice were resistant to lethal IR injury [90].
Based on these salutary animal studies, clinical trials were con-
ducted to assess NHE inhibition as a potential therapy for IR injury.
Overall, these trials did not demonstrate a beneﬁt of NHE inhibi-
tion in patients suffering from acute MI.  The ESCAMI (Evaluation
of the Safety and Cardioprotective Effects of Eniporide in Acute
Myocardial Infarction) trial found no differences in clinical out-
comes between patients receiving eniporide, a speciﬁc inhibitor of
the NHE-1 isoform (the predominant NHE expressed in the heart)
or placebo [91]. The EXPEDITION trial examined the therapeu-
tic potential of cariporide, a speciﬁc NHE-1 inhibitor, in high risk
patients undergoing coronary artery bypass graft (CABG) surgery
[92]. While the EXPEDITION trial found that NHE inhibition reduced
mortality associated with MI,  all-cause mortality was  paradoxically
increased in the NHE inhibition group due to an increased incidence
of cerebrovascular events. Therefore, the EXPEDITION investigators
concluded that the trial provided proof of concept for the cardiopro-
tective potential of NHE inhibition, but that cariporide was likely
not suitable for clinical use due to unacceptable adverse effects.
As myocyte calcium overload is responsible for much of
the irreversible injury that occurs during both ischemia and at
reperfusion, inhibition of the Na+–Ca2+ exchanger (NCX), has
been proposed to be cardioprotective. Imahashi et al. found that
Langendorff-perfused hearts of NCX KO mice sustained less necro-
sis following IR than control hearts [93]. Furthermore, a study
conducted by Kawasumi et al. found that a 30 min  intravenous
infusion of caldaret, an NCX inhibitor, at reperfusion signiﬁcantly
attenuated ischemic death in the canine heart [94]. Unfortunately,
a clinical trial examining the therapeutic efﬁcacy of caldaret, the
CASTEMI trial, provided no evidence of cardioprotection in patients
presenting with large acute ST-segment elevation MI [95].
It has been well known for many years that scavengers of
oxygen-derived free radicals could enhance contractile function
and/or reduce infarct size in animal models of myocardial ischemia.
Recombinant human superoxide dismutase administered at re-
ﬂow in the Langendorff perfused rabbit heart has been documented
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Table  1
Summary of animal studies and clinical trials assessing cardioprotective potential of interventions against known mediators of lethal reperfusion injury. IR,
ischemia–reperfusion; NHE, Na+–H+ exchanger; KO, knockout; CABG, coronary artery bypass graft; CVA, cerebrovascular accident; NCX, Na+–Ca2+ exchanger; MI, myocardial
infarction; SOD, superoxide dismutase; MPT; mitochondrial permeability transition.
IR injury mediator Study Design Results
Rapid correction
of acidosis
Karmazyn [89] Cardioprotective potential of NHE inhibitor amiloride assessed
in  isolated-perfused rat heart
Enhanced ventricular recovery in
amiloride-treated hearts
Wang et al. [90] Resistance to IR injury assessed in NHE1 KO mice using
isolated-perfused heart model
Improved ventricular function in NHE1 KO mice
ESCAMI [91] Clinical trial examining therapeutic potential of NHE1 inhibitor
eniporide when administered 10 min  before reperfusion
No reduction in infarct size or adverse outcomes
EXPEDITION [92] Clinical trial examining therapeutic potential of NHE1 inhibitor
cariporide in high risk patients undergoing CABG
Reduced MI  mortality, but increased CVA mortality
Calcium
overload
Imahashi et al. [93] Resistance to ischemic death assessed in isolated-perfused
hearts of NCX KO mice
Reduced infarct size in NCX KO hearts
Kawasumi et al. [94] Cardioprotective potential of NCX inhibitor caldaret assessed
in  in vivo canine model of MI
Reduced infarct size in caldaret-infused hearts
CASTEMI [95] Clinical trial examining therapeutic potential of NCX inhibitor
caldaret in patients presenting with ST-elevation MI
No reduction in infarct size
Oxidative stress
Ambrosio et al. [96] Ability of SOD to protect against IR injury assessed in
isolated-perfused rabbit hearts
Improved post-ischemic function in SOD hearts
Guan  et al. [97] Small clinical trial assessing therapeutic potential of xanthine
oxidase inhibitor allopurinol
Enhanced ventricular recovery in patients
receiving allopurinol
Ye  et al. [98] Meta-analysis of clinical trials assessing effect of antioxidant
vitamin supplementation on cardiac outcomes
No effect on incidence of adverse cardiovascular
events
MPT
Hausenloy et al. [101] Cardioprotective potential of MPT inhibitor cyclosporin A
t hear
Infarct size reduction when cyclosporin A
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Piot  et al. [102] Small clinical trial assessing the
cyclosporin A when administere
o improve post-ischemic contractile function [96]. Clinical trials
xamining the protective potential of attenuating oxidative stress
s a treatment for MI  have yielded conﬂicting results but, in gen-
ral, have not supported a cardioprotective role. In a small trial
nrolling 38 patients, allopurinol administered orally just after
dmission (approximately 60 min  prior to reperfusion) assisted
entricular recovery in patients undergoing angioplasty for acute
I [97]. However, a meta-analysis of clinical trials examining the
ole of antioxidant vitamin supplementation in providing protec-
ion from cardiovascular disease found no beneﬁt of antioxidant
upplementation in improving patient outcomes [98].
Because MPT  has been widely implicated as a central mediator
f reperfusion injury, and because many known cardioprotec-
ive interventions, such as inhibition of NHE and NCX, have been
hown to exert their protective effects partly through inhibition
f MPT  [28], many studies have focused on investigating methods
y which MPT  may  be directly prevented. The immunosuppress-
nt cyclosporin A (CsA) has been demonstrated to prevent MPT
99], and this prevention of MPT  has been attributed to CsA’s abil-
ty to inhibit the MPT  pore component cyclophilin D [28]. Animal
odels of myocardial IR have demonstrated that CsA administra-
ion is cardioprotective [100,101]. In a small pilot clinical trial, CsA
dministered at time of re-ﬂow to patients suffering from acute
I was demonstrated to reduce infarct size as assessed through
elease of creatine kinase and MRI, making CsA an attractive can-
idate for MI  therapy [102]. However, concerns have been raised
egarding the results of the trial, as, in some patients, reperfusion
ay  not have been initiated up to 12 h following onset of chest pain,
 time point at which few myocytes within the risk region would
emain salvageable [103]. Furthermore, there are some notable lim-
tations in regard to CsA’s cardioprotective effect. First, although
sA administration was well-tolerated in the pilot clinical trial,
sA administration can potentially elicit some adverse effects at
he level of the heart as a consequence of its interaction with
alcineurin [31]. Secondly, the therapeutic range of CsA may  be
omewhat narrow, as a study conducted by Grifﬁths and Halestrap
ound that higher doses of CsA were not protective [104]. The
rotective effect of CsA can also be overcome by enhancing thet administered at reperfusion
ic potential of
eperfusion
Infarct size reduction
stimulus of MPT, further limiting the therapeutic efﬁcacy of CsA
[28]. Thus, more work is required to establish the clinical utility of
CsA as a treatment for acute MI.
Interestingly, a recent study by Pan et al. demonstrated that
knockout of the mitochondrial calcium uniporter (MCU), which
was demonstrated to abolish both mitochondrial calcium uptake
and calcium-induced MPT, does not confer protection from IR
injury [105]. This result is surprising in light of the many studies
demonstrating that drugs and protocols that inhibit MPT, includ-
ing administration of CsA at reperfusion, elicit cardioprotection
[28]. One potential explanation as to why  MCU  knockout failed
to confer cardioprotection may  be due to the indirect effect that
MCU  knockout has on the cellular handling of calcium. Although
calcium-induced MPT  greatly predisposes myocytes to cell death
during IR, the ability of mitochondria to buffer increases in cyto-
solic calcium concentration through passive uptake of calcium via
the MCU  may  help protect cardiac myocytes from other calcium-
mediated mechanisms of irreversible injury, such as the activation
of calcium-dependent degradative enzymes and hypercontrac-
ture (discussed in Section “Reperfusion injury: calcium overload”).
However, MCU  knockout eliminates the ability of mitochondria to
uptake calcium, thereby abolishing the ability of mitochondria to
buffer rising cytosolic calcium concentrations and potentially ren-
dering MCU-deﬁcient cardiomyocytes susceptible to these other
forms of calcium overload-mediated irreversible injury. In contrast
to MCU  knockout, CsA, which reversibly inhibits MPT by binding
to the permeability transition pore component cyclophilin D,  does
not absolutely abolish the ability of mitochondria to uptake calcium
but rather increases the calcium load required for MPT  to occur
[28,106]. This qualitative difference in the mechanism of MPT  inhi-
bition may  partly explain why  CsA administration has been shown
to confer protection and MCU  knockout has not.
While it is clear from the above discussion that a great many
promising cardioprotective interventions have been described, the
fact that none of these have become implemented into standard
clinical practice underlines the importance of enhancing our
understanding of how the heart can be protected from ischemic
death, allowing for the identiﬁcation of novel targets for MI
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herapy. Although the cytoskeleton has been demonstrated to play
n important role in lethal reperfusion injury [26,35], the role of the
ytoskeleton in mediating cardioprotective signaling has received
ittle attention and is largely unknown. However, it is known that
ytoskeletal signaling has been shown to play a prominent role in
aintaining cell viability in both non-muscle cells and in cardiac
yocytes [107–109]. Furthermore, the cytosolic tyrosine kinase
ocal adhesion kinase (FAK), an essential mediator of cytoskele-
al signaling [110], has been shown by numerous studies to play
n important role in cell proliferation, survival and hypertrophy
ignaling cascades [111–113]. Based on this evidence, studies were
onducted to assess the cardioprotective potential of cytoskeletal
ignaling; the results of these studies are reviewed below in Section
Cytoskeletal signaling and cardioprotection”.
ytoskeletal signaling and cardioprotection
Because previous studies had shown that cytoskeletal lesions
re a critical determinant of irreversible cellular injury during IR
26,41], it was hypothesized that interventions that protect the
ytoskeleton from ischemic stress would be cardioprotective. Wei
nd Vander Heide demonstrated that heat stress (HS) signiﬁcantly
nhanced the expression of heat shock proteins (HSPs), proteins
apable of associating with and stabilizing the actin cytoskeleton
114,115], thereby enhancing the cell’s resistance to stress. Both
S and the dual expression of HSP27 and HSP70 protected neona-
al rat ventricular myocytes (NRVM) from cell death induced by
etabolic inhibition (simulated IR). Furthermore, HS was associ-
ted with the assembly of an integrin–paxillin–FAK cytoskeletal
ignaling complex, which was abolished through targeted inhibi-
ion of FAK via overexpression of the endogenous FAK competitive
nhibitor FRNK (FAK-related non-kinase). Interference with FAK
ctivity also enhanced NRVM cell death in response to simulated
R [47].
In subsequent studies, Wei  and Vander Heide hypothesized that
AK and cytoskeletal signaling may  represent a unique cardiopro-
ective signaling pathway elicited by myocardial stress. To test this
ypothesis, the role of FAK was directly interrogated in HS and
P-elicited signaling pathways. In cultured NRVM, HS signiﬁcantly
nhanced the FAK activation. HS also enhanced the interaction
etween FAK and PI3K, and this interaction was  associated with
nhanced expression of activated Akt. Overexpression of FRNK in
RVM reduced the expression of activated Akt following HS both at
aseline and following 10 min  of simulated ischemia, implicating
kt as a mediator of cardioprotection downstream of FAK [116].
n Langendorff perfused adult mouse hearts, IP also signiﬁcantly
nhanced the expression of activated FAK and Akt and protected the
earts from ischemic death, suggesting that cytoskeletal signaling
ay  mediate a common pathway by which myocardial stress leads
o downstream cardioprotective signaling [117].
Whereas these earlier studies utilized in vitro and ex vivo model
ystems to demonstrate activation and protection resulting from
 cytoskeletal-based cardioprotective signaling pathway, a later
tudy conducted by Perricone et al. utilized a novel myocyte-
estricted, inducible FAK KO mouse model to assess the importance
f FAK and cytoskeletal signaling in an in vivo model of MI.  This
tudy found that, while IP elicited signiﬁcant protection from lethal
R injury in control mice, the protective effect of IP was  abrogated
n FAK KO mice. Furthermore, the expression of activated PI3K and
kt was enhanced in preconditioned control hearts but not in pre-
onditioned FAK KO hearts [118], in accordance with the ﬁndings
f the results of the earlier studies conducted by Wei  and Vander
eide discussed above [116,117].
Because cytoskeletal lesions predispose cardiomyocytes to sar-
olemmal membrane rupture and cell death, mechanisms thatological Research 89 (2014) 36–45 43
either protect cellular membranes during IR or enhance the repair
of damaged membranes should be cardioprotective. Accordingly,
a study by Wang et al. assessed the cardioprotective potential of
the striated muscle-speciﬁc tripartite motif family protein MG53,
a known mediator of skeletal muscle membrane repair. This study
found that cardiomyocyte membrane damage stimulates the local-
ization of MG53 exclusively to the damaged membrane, and that
membrane healing is impaired in MG53 deﬁcient cardiomyocytes.
Importantly, genetic ablation of MG53 exacerbated IR injury in the
Langendorff-perfused mouse heart, supporting a cardioprotective
role of MG53 and membrane repair [119]. Interestingly, a study
by Cao et al. found that MG53 knockout abolished the protective
effect of IP in the Langendorff-perfused mouse heart and that over-
expression of MG53 in cultured myocytes conferred protection
from hypoxia and oxidative stress-induced cell death. This study
determined that the protective mechanism of MG53 was due to its
ability to stimulate downstream activation of PI3K-Akt and Erk1/2
signaling pathways [120]. Therefore, MG53 may exert its cardio-
protective inﬂuence through multiple mechanisms.
Conclusion
Despite the great multitude of interventions implicated as hav-
ing cardioprotective potential that have been identiﬁed over the
past several years, an efﬁcacious therapy based on what has been
learned about cardioprotection is still lacking. The fact that so many
different interventions are capable of reducing ischemic death
underlines the fact that there are likely several different path-
ways within a robust cardiac signaling network that can ultimately
elicit a cardioprotective state. The pathophysiology of ischemic
heart disease is complex, and a therapeutic strategy capable of
activating multiple arms of the cardioprotective signaling net-
work and/or simultaneously counteracting multiple mediators of
IR injury would likely have the greatest efﬁcacy in mitigating
ischemic death and improving the morbidity and mortality asso-
ciated with MI.  While the cardioprotective potential of therapies
targeting many of the mediators of IR injury have been well studied
in both animal models and clinical trials, the therapeutic poten-
tial of other mediators, especially cytoskeletal lesions and the
role of cytoskeletal signaling, have received less attention and are
not completely understood. Future studies will be important for
enhancing both our knowledge of MI  pathophysiology and mecha-
nisms of cardioprotection, thereby providing additional avenues
of cardioprotective signaling that may  be potentially harnessed
toward the ultimate goal of establishing a highly efﬁcacious thera-
peutic strategy for enhancing the heart’s resistance to myocardial
IR injury.
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